J&J Retail Traders Unfazed By Court Rejecting 3rd Talc Settlement, But Analyst Sees Stock Pullback Risk

J&J stated it would revert to the tort system to fight the talc litigation, labeling the claims as based on "junk science" and influenced by third-party litigation funding.
In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)
In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)
Profile Image
Ramakrishnan M·Stocktwits
Updated Mar 05, 2026   |   2:29 PM EST
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...

Shares of Johnson & Johnson dropped nearly 7.6% on Tuesday, marking their worst session in over six years following a court's rejection of the company's third attempt to resolve talc-related litigation through bankruptcy proceedings. Retail investors, however, appeared more resilient.

A Texas judge dismissed J&J's attempt to settle class action lawsuits related to talcum powder claims via a $10 billion Chapter 11 filing. 

The company had aimed to settle claims against its subsidiary, Red River Talc, through this bankruptcy process. 

Read Next
Loading...
Loading...

Advertisement|Remove ads.

The plaintiffs accuse J&J of promoting baby powder while knowing about its potential risks, including ovarian cancer.

Judge Christopher Lopez ruled that J&J's process for soliciting votes from tens of thousands of claimants was flawed. 

Previous attempts to address talc-related lawsuits through similar bankruptcy filings in New Jersey were dismissed in 2023.

Advertisement|Remove ads.

In response, J&J stated it would revert to the tort system to fight the talc litigation, labeling the claims as based on "junk science" and influenced by third-party litigation funding. 

J&J highlighted its strong legal track record, having won 16 out of 17 ovarian cancer cases in the past 11 years and settling 95% of mesothelioma lawsuits.

However, Stocktwits sentiment for J&J improved from 'bearish' to 'neutral,' accompanied by a 1,025% spike in message volume.

Advertisement|Remove ads.

Screenshot 2025-04-02 at 8.42.33 AM.png
JNJ sentiment and message volume as of April 1. | source: Stocktwits

Some retail traders viewed the drop as an overreaction. One user dismissed the decline as a result of “irrational fears.” 

At the same time, another pointed out J&J’s financial strength, stating, “They can afford $10B with over $24B cash and a market cap over $300 billion. No way it goes Chapter 11.”

Advertisement|Remove ads.

According to The Fly, Morgan Stanley expects Johnson & Johnson shares to retrace some of their year-to-date outperformance, with the stock up nearly 15% year-to-date versus the S&P 500's almost 5% decline. 

The analyst noted that the new ruling differs from the previous bankruptcy attempt in New Jersey, which was dismissed "due to lack of imminent and immediate financial distress."

Advertisement|Remove ads.

The firm has an 'Equal Weight' rating and a $163 price target on J&J shares, which were marginally higher in Tuesday's after-hours trading.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Comments
Share your thoughts...

Comments posted here will also appear on symbol pages.

Follow on Google News
Read about our editorial guidelines and ethics policy

Advertisement|Remove ads.